Production (Stage)
Regen BioPharma, Inc.
RGBP
$0.07
$0.028970.32%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| SG&A Expenses | 487.10K | 501.00K | 471.90K | 436.60K | 418.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 593.20K | 654.60K | 627.40K | 604.60K | 582.40K |
| Operating Income | -356.90K | -418.30K | -391.00K | -368.20K | -345.90K |
| Income Before Tax | -1.03M | -662.40K | -722.50K | -691.60K | -624.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.03 | -0.66 | -0.72 | -0.69 | -0.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.03M | -662.40K | -722.50K | -691.60K | -624.10K |
| EBIT | -356.90K | -418.30K | -391.00K | -368.20K | -345.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.18 | -0.10 | -0.10 | -0.11 | -0.11 |
| Normalized Basic EPS | -0.12 | -0.06 | -0.07 | -0.07 | -0.07 |
| EPS Diluted | -0.18 | -0.10 | -0.10 | -0.11 | -0.11 |
| Normalized Diluted EPS | -0.12 | -0.06 | -0.07 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 29.46M | 28.94M | 27.98M | 26.32M | 21.75M |
| Average Diluted Shares Outstanding | 29.46M | 28.94M | 27.98M | 26.32M | 21.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |